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Accepted 24 August 2009AbstractCondensation: Both Gonal-F and Puregon, especially in their high-dosage administration, might inhibit the endometrial cell proliferation in the
initial 48-hour culture. After 72-hour culture, Gonal-F persisted the inhibition of the endometrial growth, whereas Puregon reversed its effect to
enhance endometrial growth.
Objectives: Endometrial proliferation or regeneration during menstrual cycle is regulated by sexual hormones. However, the effect of gonad-
otropins on the endometrial cell growth remains obscure. Herein, we aimed to investigate the effects of recombinant follicle-stimulating
hormones (r-FSHs) (Gonal-F and Puregon) on the proliferation of human endometrial cells in vitro.
Materials and Methods: Human endometrial cells (RL95-2 cells) were obtained commercially and cultured in the serum-containing media in the
presence of r-FSHs (Gonal-F and Puregon at concentrations of 0 mIU/mL, 200 mIU/mL, 400 mIU/mL, and 600 mIU/mL) up to 72 hours.
According to the gonadotropin concentrations, all cultured endometrial cells were divided into four groups: (1) 0 mIU/mL (control); (2)
200 mIU/mL; (3) 400 mIU/mL; and (4) 600 mIU/mL. After 72-hour culture, endometrial cell proliferations were assessed overnight by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The influences of different r-FSH agents and dosages on endometrial cell
proliferation in each group were evaluated and compared.
Results: In the four Gonal-F groups, the cell absorption (control and 200 mIU/mL, 400 mIU/mL, and 600 mIU/mL Gonal-F) after 24/48/72-hour
cultures were as follows: (1) 0.57/0.7/0.82; (2) 0.56/0.66/0.78; (3) 0.55/0.64/0.77; and (4) 0.51/0.61/0.78. After 48 hours, higher dosage of
Gonal-F appeared to significantly inhibit the endometrial cell proliferation. After 72-hour culture, all three dosages of Gonal-F appeared to
inhibit the endometrial cell proliferation similarly. In Puregon groups, the cell absorptions were as follows: (1) 0.62/0.53/0.62; (2) 0.61/0.5/0.66;
(3) 0.61/0.49/0.66; and (4) 0.64/0.49/0.66. Puregon administration displayed initial inhibition and subsequent stimulation effects on the
endometrial cells.
Conclusions: Both Gonal-F and Puregon, especially in their high-dosage administration, appeared to inhibit the endometrial cell proliferation in
the initial 48-hour culture. After 72-hour culture, Gonal-F persisted the inhibition of the endometrium, whereas Puregon reversed its effect by
enhancing the endometrial growth. The differences might be because of the different formulations or molecular structures existing between alpha
and beta follitropins.
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Adequate endometrial development is one of the factors
that play a significant role in early pregnancy. Endometrial
growth is thought to depend on numerous factors, including
hormones, lifestyle, uterine artery blood flow, posture, and
others. Endometrial proliferation or regeneration during
menstrual cycle is regulated by sexual hormones. A change in
endometrial pattern and a decrease in endometrial and sub-
endometrial blood flows are critical for the subsequent
implantation of embryos. During the menstrual cycle, the
endometrium undergoes cyclic proliferative and secretory
changes in preparation for implantation. If this preparation is
not sufficient, the implantation will fail.
The importance of endometrial development in in vitro
fertilization (IVF) outcome has been previously reported. In
the follicular phase, the growing follicles produce increasing
amounts of estradiol that would induce proliferative endo-
metrial changes. After ovulation, the corpus luteum produces
progesterone that would initiate secretary changes. If
implantation does not occur in the window of implantation, the
endometrium will shed once the corpus luteum regresses.
Thicker endometrium might improve the pregnancy rate [1].
With certain endometrial abnormalities (e.g. Asherman’s
syndrome) that prevent normal endometrial changes from
occurring, implantation rates are low and abortion rates are
high [2].
Numerous hormones might influence the endometrial
proliferation and cyclic changes. Follicle-stimulating hormones
(FSHs) have been known to directly act on endometrium, which
results in the decidualization of endometrial cells [3]. FSH
receptors have not been proven to be present in the human
endometrium. However, myometrial and endometrial cancer
cells have been known to contain FSH receptors [4,5].
Furthermore, other hormone receptors, such as LH/hCG
receptor, have been shown to be present in human endometrium
[6e8].
Recombinant FSH (r-FSH) has been routinely used for
controlled ovarian hyperstimulation (COH) during assisted
reproduction procedures. Two popular r-FSHs, follitropin
alpha (Gonal-F; Serono, Rome, Italy) and follitropin beta
(Puregon; Organon, Oss, The Netherlands), have been popu-
larly used for years. There are numerous reports comparing
their clinical applications in IVF. Most literatures demon-
strated their comparable clinical results [9]. However, the
effect of these recombinant gonadotropins on the endometrial
cell growth remains obscure.
Reviewing the MEDLINE database, no investigators
demonstrated the influence of r-FSH on endometrial prolifer-
ation. Ku et al [10] demonstrated the inhibitive effects of
human menopausal gonadotropin (hMG) and urinary FSH
(u-FSH, Metrodin; Serono) on endometrial cell proliferation.
Besides this, there is no literature concerning the roles of
recombinant gonadotropins in the endometrial proliferation in
vivo or in vitro. Herein, we aimed to investigate the effects of
r-FSH (Gonal-F and Puregon) on the proliferation of humanendometrial cells in vitro. To the best of our knowledge, this is
the first report about the related issue.
Materials and methods
Human endometrial carcinoma (RL95-2 cell line) was
derived from Food Industry Research and Development Insti-
tute. Human endometrial cells were maintained in 90% of a 1:1
mixture of Dulbecco’s Modified Eagle Medium (DMEM) and
Ham’s F12 medium containing 1.2 g/L sodium bicarbonate;
5 mg/mL bovine insulin; 15 mM HEPES (Gibco BRL, Gai-
thersburg, MD, USA); and 10% heat-inactivated fetal bovine
serum (Hyclone, Logan, UT, USA). Cell growth was evaluated
microscopically with an inverted-phase microscope. Human
endometrial cells were cultured in the serum-containing media
in the presence or absence of Gonal-F and Puregon for 72 hours.
According to the gonadotropin concentrations, all cultured
endometrial cells were divided into four groups: (1) 0 mIU/mL
(control); (2) 200 mIU/mL; (3) 400 mIU/mL; and (4)
600 mIU/mL. Human endometrium cells were counted by
hemocytometer and seeded in 96-well plates (Corning, NY,
USA) at 1 104 cells/well to 3 104 cells/well. Cells were
grown at 37C with medium alone (control) or 200 mIU/mL,
400 mIU/mL, and 600 mIU/mL of Gonal-F and Puregon. The
culture procedures and determination and classification of
gonadotropin dosages were modified after referring Ku et al’s
work [10].
The Cell Proliferation Kit I assay (Roche Applied Science,
68298 Mannheim, Germany) was used to assess the gonado-
tropins’ influences on cell growth. After 72-hour culture,
endometrial cell proliferations were assessed overnight by
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
assay. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide was added to the culture wells for 4 hours,
after which the cells were solubilized overnight at 37C;
absorbance at 595 nm was recorded using an enzyme-linked
immunosorbent assay plate reader (Bio-Rad, Philadelphia, PA,
USA). The influences of different r-FSH agents and dosages on
endometrial cell proliferation in each group were evaluated and
compared. All experiments were performed in triplicate using
eight wells for each treatment. Optical densities were
compared between the treatment groups and the controls
incubated with medium alone. The intra- and interassay coef-
ficients of variation were less than 5% and 6%, respectively.Statistical analysisCell proliferation data were expressed as ratio influence of
control culture proliferation. All results were normalized to
cellular protein content, and the data were examined for equal
variance and normal distribution before statistical analysis.
The mean values were compared by analysis of variance with
Fisher’s least significant difference method for comparing
groups [11]. Standard errors were within 10% of the mean of
replicate wells. A p value less than 0.05 was considered
statistically significant.
Fig. 2. Effects of different Gonal-F dosages on human endometrial cell growth.
Results are expressed as a percentage of the control condition (culture medium
with Gonal-F addition).
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In the four Gonal-F groups, the cell absorptions (control and
200 mIU/mL, 400 mIU/mL, and 600 mIU/mL Gonal-F) after
24/48/72-hour cultures were listed as follows: (1) 0.57/0.7/0.82;
(2) 0.56/0.66/0.78; (3) 0.55/0.64/0.77; and (4) 0.51/0.61/0.78
(Figs. 1AeC). In the first 24 hours, low- or moderate-dosage
(200 mIU/mL or 400 mIU/mL) Gonal-F appeared to have
nonsignificant influences on the endometrial growth. In
contrast, high Gonal-F dosage (600 mIU/mL) appeared to
inhibit endometrial growth (Fig. 1A). In 48 hours, cell prolif-
eration appeared to be negatively correlated with the Gonal-F
dosage. Higher dosage of Gonal-F appeared to significantly
inhibit the endometrial cell proliferation (Fig. 1B). After
72-hour culture, all three dosages of Gonal-F appeared to
similarly inhibit the endometrial cell proliferation (Fig. 1C).
In Fig. 2, we observe the clear trend of initial inhibition of
high-dosage Gonal-F administration for the endometrial cells.
In proportion to the normal controls, the absorption ratios for
the (1) control and (2) 200 mIU/mL, (3) 400 mIU/mL, and (4)
600 mIU/mL Gonal-F after 24/48/72-hour cultures were as
follows: (1) 100 4.8/100 3.8/100 7.3; (2) 98.4 0.9/
94.9 3.7/94.5 0.8; (3) 95.6 2.2/91.1 2.2/93.7 0.7;
and (4) 89.9 2.3/87.7 1.6/94.3 4.7, respectively. High-
dosage Gonal-F significantly inhibited cell growth compared
with low-dosage Gonal-F. However, the inhibition of0.51 ± 0.02
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Fig. 1. Dose-dependent influence of Gonal-F, at different concentrations (0 mIU/m
for (A) 24 hr, (B) 48 hr, and (C) 72 hr, compared with the growth of controls treated
among controls and 200-mIU/mL and 400-mIU/mL groups; p< 0.05 for 600-mIU
Gonal-F ( p< 0.05 between 4 groups). (C) Culture for 72 hr with Gonal-F ( p< 0.0
(200 mIU/mL, 400 mIU/mL, and 600 mIU/mL); p< 0.05 for Gonal-F groups comendometrial cells might be transient and might return to
comparable levels as that in low-dosage Gonal-F (Fig. 2).
In the four Puregon groups, the cell absorptions after 24/
48/72-hour cultures were listed as follows: (1) 0.62/0.53/0.62;
(2) 0.61/0.5/0.66; (3) 0.61/0.49/0.66; and (4) 0.64/0.49/0.66
(Figs. 3AeC). In the first 24 hours, low-dosage Puregon
(200 mIU/mL and 400 mIU/mL) appeared to have a nonsignif-
icant influence on the endometrial cell proliferation. In contrast,
high-dosage Puregon (600 mIU/mL) appeared to stimulate
endometrial growth (Fig. 3A). After 48 hours, Puregon
appeared to inhibit the endometrial cell proliferation.A
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Fig. 3. Dose-dependent influence of Puregon, at different concentrations (0 mIU/mL, 200 mIU/mL, 400 mIU/mL, and 600 mIU/mL), on human endometrial cells
for (A) 24 hr, (B) 48 hr, and (C) 72 hr, compared with the growth of controls treated with culture medium alone. Values represent mean standard error. (A)
Culture for 24 hr with Puregon (NS difference between controls and 200-mIU/mL and 400-mIU/mL groups; p< 0.05 for 600-mIU/mL group compared with
controls and 200-mg and 400-mg groups). (B) Culture for 48 hr with Puregon (NS difference among 200-mg, 400-mg, and 600-mg groups; p< 0.05 for 200-mIU/
mL, 400-mIU/mL, and 600-mIU/mL groups compared with the control group). (C) Culture for 72 hr with Puregon (NS difference among 200-mg, 400-mg, and
600-mg groups; p< 0.05 for 200-mIU/mL, 400-mIU/mL, and 600-mIU/mL groups compared with the control group). NS¼ nonsignificant.
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dosage (Fig. 3B). Higher dosage of Puregon appeared to
significantly inhibit the endometrial cell proliferation (Fig. 3C).
After 72-hour culture, all three dosages of Puregon appeared to
similarly stimulate the endometrial cell proliferation (Fig. 3C).
In Fig. 4, we observe the trend of initial inhibition and
subsequent stimulation effects of Puregon on endometrial cell
proliferation. The absorption ratios for the (1) control and (2)
200 mIU/mL, (3) 400 mIU/mL, and (4) 600 mIU/mL Puregon100
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Fig. 4. Effects of Puregon on human endometrial cell growth. Results are
expressed as percentage of the control condition (culture medium with Gonal-
F addition).after 24/48/72-hour cultures were as follows: (1) 100 3.2/
100 8.7/100 6.2; (2) 98.3 0.7/93.5 0.7/106.7 1.7;
(3) 98.1 1/91.9 3/107.8 0.03; and (4) 103.1 2.2/
91.9 6/107.4 3.4, respectively. High-dosage Gonal-F
significantly inhibited cell growth compared with low-dosage
Gonal-F. However, the inhibition of endometrial cell prolif-
eration might be transient and might reverse to stimulation
effect after 72-hour culture (Fig. 2).
Discussion
Numerous variables, such as age, embryo quality, and
stimulation protocol, have a significant impact on assisted
reproduction technique outcome. Evaluation of endometrial
thickness and pattern might be beneficial to distinguish the
fertile cycles from the infertile ones. Adequate proliferation
and cyclic changes are necessary for successful implantation
to occur. Thinner endometrium is often associated with
implantation failure and abortion [12]. A minimum thickness
of 10 mm during IVF was found to produce a higher preg-
nancy rate [12]. Therefore, during COH application, clinicians
must pay close attention to endometrial development and
follicle growth.
Numerous medicine administrations during COH might
influence endometrial proliferation and pattern. The r-FSH
preparations have been introduced in IVF markets for around
one decade. Till date, there are two major r-FSHs [follitropin
alpha (Gonal-F) and follitropin beta (Puregon)] used in clinical
applications. Most literatures compared and demonstrated
their clinical folliculogenesis and pregnancy rates [9]. There
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tration of both agents [9].
Concerning the influence of other medicines on endome-
trium, clomiphene citrate (CC) administration during COH has
been well known to be associated with thin endometrium [13].
Thicker endometrium was identified among women treated
with gonadotropin when compared with those treated with CC
[14]. A similar negative endometrial effect was not observed
in the present CCþ gonadotropin cycles. The endometrial
thickness with CCþ gonadotropin was similar to that in the
simple gonadotropin cycles. The supraphysiological estradiol
level reached during CCþ gonadotropin stimulation was able
to correct for the negative endometrial effects of CC alone.
Other medicine applications might also influence the
endometrial proliferation. Estrogen supplementation during
stimulation with CC has been shown to improve endometrial
development and to result in thicker endometria and improved
morphology [15,16]. Administration of ethinyl estradiol might
reverse the deleterious effect of CC on endometrial develop-
ment during the follicular phase [17]. Obesity and hyperten-
sion have been found to increase endometrial thickness
independently [18]. In contrast, the estrogen or progesterone
receptors were correlated with endometrial pattern but not
with endometrial thickness [19]. Pre-retrieval hCG adminis-
tration does not improve the endometrial thickness [20].
In this study, we first demonstrated the possible adverse
effects of gonadotropin on the endometrial growth. Our appli-
cation of r-FSH might prevent the contamination of urinary
compounds in FSH/hMG on the endometrial proliferation and
the subsequent evaluation. These findings were compatible
with those of Ku et al [10], who demonstrated the adverse
effects of hMG and u-FSH on endometrial proliferation. Con-
cerning the gonadotropin concentration on the endometrial
proliferation, after repeat experiments, we observed their
different presentation between Gonal-F and Puregon on the
endometrial proliferation. The difference in the effects of
Gonal-F and Puregon on endometrium might be because of
their different molecular structures. These findings were also
different from those of Ku et al [10], which revealed the non-
correlations between different concentrations of u-FSH/hMG
and inhibition on endometrial cell proliferations.
In this study, the 3-day culture instead of a longer-period
culture is considered because of the limited cell growth and
the medium replacement during routine laboratory culture.
Furthermore, we also observed differences between Gonal-F
and Puregon, which might be the result of the intra- and
interexperiment variations. We should also emphasize the
possibility of an underlying difference between the human
endometrial cells and the human cancer (RL95-2) cell line.
Considering the donation limitation and the unavailability of
fresh human endometrial cells, we adopted the endometrial
tumor cell lines instead of the collection and culture of fresh
human endometrial cells. Although greater numbers of eval-
uations are needed to validate these findings, it is logical to
suspect that the different r-FSHs might exhibit different
influences on the endometrial proliferation. Our preliminary
investigation provides evidence that exogenous gonadotropinmight directly or indirectly influence endometrial growth and
the subsequent uterine receptivity. Furthermore, gonadotropin-
induced suppression of endometrial growth might be of special
concern for clinicians during ovarian hyperstimulations. It also
suggested the necessity of exogenic estrogen addition for the
individuals accepting ovarian hyperstimulation, especially
when their ultrasonography showed thin endometrium after
mid-follicular phase (<7 mm).
It is well known that the pituitary-derived FSH is a two-
subunit (alpha and beta) glycoprotein. Up to 20 different FSH
molecules with varying degrees of glycosylation can be puri-
fied [21], forming a spectrum of isoforms with differences in
charge, bioactivity, and elimination half-life [22]. FSH is
secreted by the pituitary as a microheterogeneous population in
terms of different charges, molecular weights, and in vitro and
in vivo bioactivities, with the secretion of polymorphic FSH
being linked to hormone receptor [23,24]. More glycosylated
molecules possess a longer half-life as compared with the
desialylated molecules, which, probably because of increased
plasma clearance, have a significantly decreased in vivo
bioactivity [25,26]. Therefore, the possible underlying mech-
anism of our finding is so complex and obscure. However,
the possible etiology might be the result of the different
components or numerous factors between two r-FSHs,
including the different presentations of r-FSH structures, amino
acid sequences, affiliations, formulations, potencies, pH
values, overall charge, isoforms, post-translational modifica-
tion, receptor-binding affinity, plasma half-life, and others [27].
Furthermore, differences between the human endometrial cells
and the endometrial cancer cell line (RL95-2 cell line) might
have existed. Further application on the human endometrial
cells is essential for the clarification of the related issues.
In conclusion, our preliminary results highlighted a statisti-
cally significant difference in the co-culture of different types of
r-FSH on the endometrial growth. Both Gonal-F and Puregon,
especially in their high-dosage preparation, appear to inhibit the
proliferation of endometrial cells in the initial 48-hour culture.
High-dosage gonadotropin administration might transiently
inhibit the endometrial cell proliferation in vitro, which
suggests its inhibitory role in endometrial growth during COH.
After 72-hour culture, Gonal-F persisted its inhibition on
endometrial proliferation, whereas Puregon reversed its effect
by enhancing endometrial growth. The differences might be
because of the different formulations, molecular structures, and
potencies of the alpha and beta follitropins, as well as the
subsequent stimulation or resistant effects on the hormone
receptors of the endometrial cells. Despite its limited case
numbers and conflicting outcomes between different r-FSHs,
this study provided the preliminary database for the future
surveys on the effects of gonadotropin on endometrium during
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